Blade Therapeutics to Present at the Stifel 2019 Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov 14, 2019--
Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, today announced that Wendye Robbins, M.D., President and Chief Executive Officer, will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 1:50 p.m. Eastern Time.
About Blade Therapeutics
Blade Therapeutics is a private, clinical-stage biopharmaceutical company advancing novel anti-fibrotic therapies to meet important patient needs. Blade’s lead compound, BLD-2660, is a highly selective calpain inhibitor targeted for the treatment of chronic fibrotic diseases. BLD-2660 recently completed a Phase I, healthy volunteer, dose escalation study in Australia. The Company plans to submit a CTN application to initiate a Phase II trial in patients with idiopathic pulmonary fibrosis in early 2020. Blade’s second candidate, BLD-0409, is a Phase I ready autotaxin inhibitor for the treatment of multiple fibrotic diseases. The Company plans to initiate a Phase 1 study for BLD-0409 in 1Q 2020.
Blade has assembled a critical mass of anti-fibrotic drug development expertise within its top-tier leadership team and a world-class network of advisors. Lead investors in Blade include MPM Capital, Deerfield, Pfizer Ventures, One Ventures, Osage Partners, Bristol-Myers Squibb and Novartis Institute of Biomedical Research. Please visit http://www.blademed.com/ for more information.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191114005221/en/
CONTACT: Blade Therapeutics
Wendye Robbins, M.D., President and CEO
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA NEW YORK
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH
SOURCE: Blade Therapeutics
Copyright Business Wire 2019.
PUB: 11/14/2019 08:00 AM/DISC: 11/14/2019 08:01 AM